Oxolife, the specialized biotech focused on enhancing embryo implantation in women undergoing Assisted Reproductive Technology (ART) fertility treatment, today announces it has appointed globally reno...
Read moreThe start-ups Oxolife, Peptomyc and aptaTargets, with which GENESIS Biomed collaborates, are advancing in their maturity with the initiation and development of clinical phases and are approaching an e...
Read moreIt is estimated that infertility affects over 75 million women around the world and over 3 million assisted reproductive techniques are performed each year. In Spain, assisted reproduction treatments ...
Read moreOxolife, la biotecnológica enfocada a tratar la infertilidad femenina, y el grupo de Balance Energético, Pubertad y Salud Reproductiva, de la Universidad de Córdoba han establecido una colaboració...
Read moreThe SARS-CoV-2 pandemic that is hitting many countries has clearly affected the medical start-up and spin-off ecosystem. After talking to some of the companies we support we have seen that it has not ...
Read moreThe biotech company Oxolife, created to develop a new treatment to improve the female fertility rate, completed its first funding round by raising 5,000,000 euros in an investment led by Inveready Ass...
Read moreAgnès Arbat and Ignasi Canals lead Oxolife, a startup that is developing OXO-001, a drug with the potential to treat female infertility as it increases the chances of embryo implantation a 65%. Arba...
Read moreAgnès Arbat y Ignasi Canals lideran Oxolife, una startup que desarrolla OXO-001, un fármaco con el potencial de tratar la infertilidad femenina al incrementar en un 65% la implantación embrionar...
Read more